Regulatory Affairs, SaMD & Digital Health Expert
I like to write about people, the places they live and the things with which they choose to surround themselves. Here are some of my favorite pieces that made it into Article.
Key Takeaways Federal regulators issued around 100 warning letters to pharmaceutical companies and healthcare providers. The letters targeted misleading advertising practices from major drugmakers and telehealth companies. Experts question if the FDA has enough resources to effectively follow up on these warnings. Understanding the Recent FDA Action on Pharmaceutical Advertising In a surprising step, federal …
The Curious Case of Pharmaceutical Ads in the U.S. Pharmaceutical ads in the U.S. draw strong reactions—some people find them annoying, others absurd. Interestingly, the U.S. is one of only two high-income countries that allow these direct-to-consumer ads, the other being New Zealand. So, what gives? Why haven’t we put a stop to these ads? …
Tackling Deceptive Drug Advertisements: A New Push for Transparency The pharmaceutical advertising landscape is changing. Recently, President Trump instructed Health Secretary Robert F. Kennedy Jr. to take action against misleading direct-to-consumer drug ads. This decision comes at a time when the Food and Drug Administration (FDA) is stepping up its enforcement against deceptive advertising practices. …
FDA’s Upcoming Meeting on Digital Health: What You Need to Know Key Takeaways: The FDA will hold a virtual meeting for digital health advisors on November 6. This meeting aims to address challenges related to AI and tech regulation in healthcare. Agenda details and discussion questions will be shared closer to the meeting date. On …
Are FDA Expert Panels Jeopardizing Public Trust? The Food and Drug Administration (FDA) is a cornerstone of public health in America, guiding crucial decisions that affect our lives. However, recent developments raise serious concerns about how the agency is operating. In recent months, the FDA has started using ad-hoc “expert panels” for important decision-making processes …
Key Takeaways Recent FDA inspections revealed serious issues at a manufacturing plant acquired by Novo Nordisk. Problems include cat hair, pests, and failures in equipment. These concerns affect not just Novo Nordisk, but also other pharmaceutical companies relying on this facility. Wall Street analysts are watching closely for potential impacts on the drug market. Historical …
Key Takeaways The FDA has approved updated COVID boosters while ending emergency use authorizations for the vaccines. The changes mainly affect availability for children under 5, as vaccines will now only be available to higher-risk groups. Ongoing clinical trials are required for future approvals, aimed at ensuring safety and efficacy. Understanding the Latest Developments in …
The Make America Healthy Again Movement: Where It Stands The Make America Healthy Again (MAHA) movement emerged as a surprising twist in American political health discourse. It was born on a hot August day when Robert F. Kennedy Jr. endorsed Donald Trump after a tumultuous presidential bid. This endorsement was punctuated by a catchy slogan …
FDA Now Offers Daily Updates on Adverse Drug Events The Food and Drug Administration (FDA) recently made a significant change in how it shares information about drug safety. Starting now, the FDA will publish reports on adverse events related to drugs and biological products every day. Previously, this information was only updated once every few …
Understanding the Impact of FDA Decisions on Biotech Trials In the world of biotechnology, regulatory decisions can have ripple effects that extend beyond the immediate concern. Recently, a notable case involved the FDA’s rejection of a skin cancer therapy developed by Replimune Group. This decision didn’t just affect Replimune; it led to the abrupt pause …